471 related articles for article (PubMed ID: 9128303)
1. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Sharma P; Sampliner RE; Camargo E
Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
[TBL] [Abstract][Full Text] [Related]
2. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
Sampliner RE
Am J Gastroenterol; 1994 Oct; 89(10):1844-8. PubMed ID: 7942680
[TBL] [Abstract][Full Text] [Related]
3. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Ouatu-Lascar R; Triadafilopoulos G
Am J Gastroenterol; 1998 May; 93(5):711-6. PubMed ID: 9625114
[TBL] [Abstract][Full Text] [Related]
4. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus.
Triadafilopoulos G; Kaczynska M; Iwane M
Am J Gastroenterol; 1996 Jan; 91(1):65-74. PubMed ID: 8561146
[TBL] [Abstract][Full Text] [Related]
5. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
6. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
7. Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus.
Sampliner RE; Camargo L; Fass R
Am J Gastroenterol; 2002 Feb; 97(2):270-2. PubMed ID: 11866260
[TBL] [Abstract][Full Text] [Related]
8. Squamous islands in Barrett's esophagus: what lies underneath?
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1998 Mar; 93(3):332-5. PubMed ID: 9517634
[TBL] [Abstract][Full Text] [Related]
9. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
Menges M; Müller M; Zeitz M
Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
[TBL] [Abstract][Full Text] [Related]
10. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
11. Relationship between rate of change in acid exposure along the esophagus and length of Barrett's epithelium.
Tharalson EF; Martinez SD; Garewal HS; Sampliner RE; Cui H; Pulliam G; Fass R
Am J Gastroenterol; 2002 Apr; 97(4):851-6. PubMed ID: 12003418
[TBL] [Abstract][Full Text] [Related]
12. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of Barrett esophagus with argon plasma coagulation with acid suppression--a prospective study].
Martin WR; Jakobs R; Spiethoff A; Maass S; Riemann JF
Z Gastroenterol; 1999 Sep; 37(9):779-84. PubMed ID: 10522363
[TBL] [Abstract][Full Text] [Related]
14. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus.
Loughney T; Maydonovitch CL; Wong RK
Am J Gastroenterol; 1998 Jun; 93(6):916-9. PubMed ID: 9647018
[TBL] [Abstract][Full Text] [Related]
15. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis?
Coenraad M; Masclee AA; Straathof JW; Ganesh S; Griffioen G; Lamers CB
Am J Gastroenterol; 1998 Jul; 93(7):1068-72. PubMed ID: 9672332
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression.
Kahaleh M; Van Laethem JL; Nagy N; Cremer M; Devière J
Endoscopy; 2002 Dec; 34(12):950-5. PubMed ID: 12471537
[TBL] [Abstract][Full Text] [Related]
17. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
Todd JA; Basu KK; de Caestecker JS
Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
[TBL] [Abstract][Full Text] [Related]
18. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3420-6. PubMed ID: 10606297
[TBL] [Abstract][Full Text] [Related]
19. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.
Gurski RR; Peters JH; Hagen JA; DeMeester SR; Bremner CG; Chandrasoma PT; DeMeester TR
J Am Coll Surg; 2003 May; 196(5):706-12; discussion 712-3. PubMed ID: 12742201
[TBL] [Abstract][Full Text] [Related]
20. High power setting argon plasma coagulation for the eradication of Barrett's esophagus.
Pereira-Lima JC; Busnello JV; Saul C; Toneloto EB; Lopes CV; Rynkowski CB; Blaya C
Am J Gastroenterol; 2000 Jul; 95(7):1661-8. PubMed ID: 10925965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
